Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB cells-based cancer vaccine
- Development stage
- Preclinical
- Lead developer
- Stembio
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous, Intratumoral, Intraperitoneal, Intradermal
01
Overview
SB cells-based cancer vaccine is a preclinical-stage cell therapy being developed by StemBios Technologies. The vaccine utilizes the company's proprietary 'SB Cells'—a population of small, pluripotent-like stem cells isolated from adult peripheral blood—which are differentiated into dendritic cells (DCs). These DCs are then loaded with tumor-associated antigens to serve as a personalized or off-the-shelf immunotherapy. The primary mechanism of action involves the presentation of these antigens to the patient's T cells, thereby stimulating a robust and specific cytotoxic immune response against malignant cells. This approach aims to overcome the limitations of traditional dendritic cell vaccines by providing a more potent and scalable source of antigen-presenting cells.
- Other names
- SB Cells cancer vaccineStemBios cancer vaccine
02
Targets
γδ TCR (T-cell receptor)Tumor-associated antigens presented by SB cell-derived dendritic cells
Beyond the preview
Go deeper on SB cells-based cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB cells-based cancer vaccine.